Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Maintains $16 Price Target
Monte Rosa Therapeutics +93.87% Pre
Monte Rosa Therapeutics GLUE | 9.48 9.60 | +93.87% +1.27% Pre |
Piper Sandler analyst Edward Tenthoff reiterates Monte Rosa Therapeutics (NASDAQ:
GLUE) with a Overweight and maintains $16 price target.